Grifols Reports Strong Q3 Results with Biopharma Growth
Nov 7, 2024 · Grifols, a global leader in plasma-derived medicines, reported a strong third quarter in 2024, with a 12.1% growth in Biopharma driving total revenues to 1.793 billion euros. The company achieved ...
Grifols on track to meet 2024 targets as core earnings rise
Follow. MADRID, Nov 7 (Reuters) - Spanish drugmaker Grifols <GRLS.MC> said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the third quarter from the ...
Grifols Delivers Strong Third-Quarter Performance Led by …
Barcelona, Spain – November 7, 2024 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, reported strong third quarter results, delivering sequential improvement across key metrics.. Nacho Abia, Chief Executive Officer, commented, “I am proud of the strong third quarter performance delivered by the entire Grifols team.
Press Releases - Grifols.com
Jul 4, 2024 · Grifols appoints Rahul Srinivasan as new Chief Financial Officer July 4 2024. Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years July 1 2024. Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group June 18 2024.
Grifols Posts Rising Profit on Biopharma Sales, Repeats Guidance
Nov 7, 2024 · Grifols SA, the Spanish pharmaceutical company hit by a short seller attack this year, reported rising profit in the third quarter and repeated its full-year guidance. Adjusted earnings before interest, taxes, depreciation, and amortization rose 27% to €462 million ($498 million), Grifols said Thursday, in line with analysts’ estimates ...
Grifols on track to meet 2024 targets as core earnings rise - MSN
MADRID (Reuters) -Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the third quarter from the same period a year ago ...
Grifols SA Reports Strong Third Quarter Growth - Markets Insider
6 days ago · In the third quarter of 2024, Grifols reported a robust financial performance, with a notable 12.4% increase in total revenue, reaching EUR 1,793 million, primarily driven by the Biopharma segment.
Grifols Accelerates Plan to Cut Chairman’s Executive Powers
Sep 23, 2024 · Grifols SA has accelerated a plan to cut Chairman Thomas Glanzmann’s executive powers as the Spanish drugmaker seeks to bolster its corporate governance amid a takeover approach.
Grifols gains after report Brookfield still pursuing possible ... - MSN
Grifols (NASDAQ:GRFS) rose 4% after a report that Brookfield Asset Management (BAM) is still evaluating a takeover of the Spanish drugmaker and is confident it has the funding for a deal.
Grifols says founding family, Brookfield looking to delist drugmaker
Jul 9, 2024 · LONDON/MADRID/BARCELONA, July 8 (Reuters) - The Grifols family and Canadian fund Brookfield (BN.TO) have agreed to evaluate a possible joint takeover bid for beleaguered Spanish drugmaker Grifols...